Building on previous work by the vector-engineering lab of Ben Deverman at the Broad ... They also plan to develop a strategy ...

Benefiting from technological and conceptual groundwork and positive early data, gene therapies are advancing in the clinic ...

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces it has submitted a ...

ROCKVILLE, MD, USA I January 14, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) today announced a strategic partnership ...